HERG potency estimates based upon dose solution analysis: What have we learned?

Journal of Pharmacological and Toxicological Methods

Volumn 64, Issue 3, 2011, Pages 251-257

  Qu, Yusheng ^a   Schnier, Paul ^a   Zanon, Roger ^a   Vargas, Hugo M ^a  

^a AMGEN INC   (United States)

Author keywords

Actual concentration; CLogP; Dose solution analysis; HERG; Nominal concentration; Solubility

Indexed keywords

POTASSIUM CHANNEL HERG;

ACCURACY; ANALYTIC METHOD; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE SOLUTION ANALYSIS; IC 50; INTERMETHOD COMPARISON; LIPOPHILICITY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PKA;

CELL LINE, TRANSFORMED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; SOLUBILITY; SOLUTIONS;

EID: 81955160725     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2011.08.004     Document Type: Article

References (20)

1. Bhattachar S.N., Deschenes L.A., Wesley J.A. Solubility: It's not just for physical chemists. Drug Discovery Today 2006, 11:1012-1018.
2. Brimecombe J.C., Kirsch G.E., Brown A.M. Test article concentrations in the hERG assay: Losses through the perfusion, solubility and stability. Journal of Pharmacological and Toxicological Methods 2009, 59:29-34.
3. Gintant G. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Pharmacology and Therapeutics 2011, 129:109-119.
4. Guth B.D. Preclinical cardiovascular risk assessment in modern drug development. Toxicological Sciences 2007, 97:4-20.
5. Hamill O.P., Neher E., Sakmann B., Sigworth F.J. Improved patch-clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflugers Archive 1981, 391:85-100.
6. Hanson L.A., Bass A.S., Gintant G., Mittelstadt S., Rampe D., Thomas K. ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation. Journal of Pharmacological and Toxicological Methods 2006, 54:116-119.
7. Herron W., Towers C., Templeton A. Experiences in method development for the analysis of in vitro study solutions for content. Journal of Pharmacological and Toxicological Methods 2004, 49:211-216.
8. Jamieson C., Moir E.M., Rankovic Z., Wishart G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. Journal of Medicinal Chemistry 2006, 49:5029-5046.
9. Leeson P.D., Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Reviews Drug Discovery 2007, 6:881-890.
10. Lipinski C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today 2004, 1:337-341.
11. Margulis M., Sorota S., Chu I., Soares A., Priestley T., Nomeir A.A. Protein binding-dependent decreases in hERG channel blocker potency assessed by whole-cell voltage clamp in serum. Journal of Cardiovascular Pharmacology 2010, 55:368-376.
12. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences USA 2000, 97:1229-12333.
13. Redfern W.S., Caulsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58(1):32-45.
14. Sawada K. Depression of the delayed outward K current by novel class III antiarrhythmi agent, E-4031, in guinea pig single ventricular cells. Journal of Molecular and Cellular Cardiology 1989, 21(suppl II):S20.
15. Tan H., Semin D., Wacker M., Cheetham J. An automated screening assay for determination of aqueous equilibrium solubility enabling SPR during drug lead optimization. Journal of the Association for Laboratory Automation 2005, 10:364-373.
16. Vargas H.M., Bass A.S., Breidenbach A., Feldman H.S., Gintant G.A., Harmer A.R., et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. Journal of Pharmacological and Toxicological Methods 2008, 58:72-76.
17. th annual Meeting Abstract #36 2007.
18. Vargas H.M., Qu Y. hERG potency estimation and dose solution analysis: What have we learned?. Journal of Pharmacological and Toxicological Methods 2008, 58:155.
19. Waring M.J., Johnstone C. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorganics and Medicinal Chemistry Lettters 2007, 17:1759-1764.
20. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophysics Journal 1998, 74:230-241.